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Abstract
Colorectal cancer (CRC) is the third most common cancer in the word. Liver metastasis is the most common site of
colorectal metastases. The prognosis of resectable colorectal liver metastases (CRLM) was improved in the recent
years with the consideration of chemotherapy and surgical resection as part of the multidisciplinary management
of the disease; the current 5-year survival rates after resection of liver metastases are 25% to 40%. Resectable
synchronous or metachronous liver metastases should be treated with perioperative chemotherapy based on three
months of FOLFOX4 (5-fluorouracil [5FU], folinic acid [LV], and oxaliplatin) chemotherapy before surgery and three
months after surgery. In the case of primary surgery, pseudo-adjuvant chemotherapy for 6 months, based on
5FU/LV, FOLFOX4, XELOX (capecitabine and oxaliplatin) or FOLFIRI (5FU/LV and irinotecan), should be indicated. In
potentially resectable disease, primary chemotherapy based on more intensive regimens such as FOLFIRINOX
(5FU/LV, irinotecan and oxaliplatin) should be considered to enhance the chance of cure. The palliative
chemotherapy based on FOLFIRI, or FOLFOX4/XELOX with or without targeted therapies, is the mainstay treatment
of unresectable disease. This review would provide additional insight into the problem of optimal integration of
chemotherapy and surgery in the management of CRLM.
Background
Colorectal cancer (CRC) is the third most commonly
diagnosed cancer in males and the second in females. It
is the second most deathly cancer worldwide. About 1.2
million new cases and 608,700 deaths were reported to
have occurred in 2008. However, the mortality rates
have been decreasing dramatically in western countries
largely resulting from improved treatment and increased
awareness and early detection [1].
Liver is the most common site of metastasis from col-
orectal cancers (50-60% of the cases). Close to one third
of patients have liver metastases either at the time of
diagnosis (synchronous in 1/3 of the cases) or during
the disease course (metachronous in 2/3 of the cases).
The prognosis of colorectal liver metastases (CRLM)
has improved in the last few years. Surgical resection of
liver metastases is considered the only curative treat-
ment option for patients with resectable liver metastases
and no extrahepatic disease [2,3]. Five years survival has
increased from <8%, using palliative chemotherapy (CT),
to 25-40% using multimodal management including CT
and surgery [1,2,4-7]
Liver metastases are resectable in only 15% of the
cases. Eighty five percents of the patients are ineligible
to surgery because of the location, the size, the number
of liver metastases, the residual normal liver, and the
extra hepatic disease [2,8]. After primary surgery, the
rate of relapse is high. This has led the investigators to
evaluate the role of neoadjuvant and adjuvant CT in the
management of these patients [9]. Furthermore, neoad-
juvant CT is being increasingly used to downsize CRLM
and render 10% to 30% of initially unresectable patients
potentially resectable [8,10]. Local hepatic arterial infu-
sion (HAI) CT after liver resection has proved to be
effective; however, this technique is not widely used,
because of concern of complications and the technical
difficulties [11-13].
In general, the term neoadjuvant is used when the CT
treatment is given preoperatively, adjuvant when the CT
treatment is given postoperatively, and perioperative
when the CT treatment is given both before and after
surgery.
Limited data analyzed the role of targeted therapies
(Bevacizumab and Cetuximab) in preoperative setting.
The predictor factors such as K-RAS are crucial before
the indication of optimal targeted therapy.
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Strategies of literature research
The present review was based on a systematic literature
search of Medline (Pubmed), last accessed 21 August
2011. The abstracts of papers presented at the annual
meetings of the American Society of Medical Oncology
(ASCO) were also analyzed. The key words used were:
colorectal cancer, liver metastases, chemotherapy, tar-
geted therapies, neoadjuvant, perioperative, adjuvant,
steatohepatitis, and sinusoidal obstruction. All phases III
and metanalyses are included. Selected phases II studies
are also analyzed. Studies assessing local HAICT are
excluded.
Standard chemotherapy in metastatic setting
Prior to 2000, standard treatment for metastatic colorec-
tal cancer was based on palliative CT using single-agent
5FU (or fluoropyrimidine drugs) combined with folinic
acid (LV). The response rate with 5FU and folinic acid
(5FU/LV) is approximately 20%. Initial randomized stu-
dies confirmed that regimen based on 5FU/LV,
improved median survival of patients with metastatic
disease from 8 to 12 months [14]. Subsequently the
combination of 5FU with oxaliplatin typically FOLFOX
or XELOX (capecitabine and oxaliplatin) and irinotecan
typically FOLFIRI or XELIRI (capecitabine and irinote-
can), has yielded overall response rate (ORR) of between
20-30% to 40-50%, and median overall survival (OS) of
between 12 to 20 months [15-18].
The optimal sequencing of these two standard CT
(FOLFOX or FOLFIRI) was evaluated by Tournigand
and collaborators. They confirmed the survival equiva-
lence of the two therapeutic sequences: FOLFOX first
then FOLFIRI or FOLFIRI first then FOLFOX. However,
the FOLFOX first was associated with a higher complete
response rates (CRR) than FOLFIRI (4.5 vs. 2.8%). In
addition, in the FOLFOX arm, 22% of patients received
surgery for liver metastases vs. 9% in FOLFIRI arm (p =
0.02), leading to the usual use of FOLFOX CT in neoad-
juvant setting. Toxicity profile of these 2 standard regi-
mens was different. Grade 3/4 mucositis, nausea/
vomiting, and grade 2 alopecia were more frequent with
FOLFIRI, and grade 3/4 neutropenia and neurosensory
toxicity were more frequent with FOLFOX [19].
A pooled analysis of seven randomized studies showed
that survival is enhanced by the administration of all the
t h r e ea c t i v ea g e n t s ,i r r e s p e c t i v eo ft h e i rs e q u e n c e .A n
interesting finding of this last analysis is that only 50-
8 0 %o fp a t i e n t sa r es u i t a b l ef o ras e c o n dl i n eC Ta n d
ultimately received the three drugs [20]. In the attempt
to enhance treatment results and to increase the
proportion of patients exposed to all active agents, a
combined administration of 5FU/LV, irinotecan and
oxaliplatin (FOLFIRINOX) has been developed. The
FOLFIRINOX was evaluated in first line in comparison
with the standard FOLFIRI, in 2 randomized phase III
studies [21,22]. In a well designed study, FOLFIRINOX
showed to be more effective (in ORR, progression free
survival [PFS] and OS) than FOLFIRI and was associated
with a higher secondary resection rate of liver metas-
tases (36% vs. 12%; p = 0.017). This regimen was parti-
cularly toxic (grade 3/4 neutropenia = 50% vs. 28%) and
requires special precautions [21]. The pooled analyses of
theses 2 randomized studies confirmed these positives
results [23]. FOLFIRINOX is an interesting regimen par-
ticularly in neoadjuvant setting for the management of
potentially resectables CRLM.
The progress in molecular biology has prompted the
investigators to develop new molecules targeting specific
abnormalities in the cancer cells, with a very acceptable
toxicity profile. Additional improvements in outcome
have been associated with the use of biological agents in
combination with cytotoxic CT. Two molecules are cur-
rently included in the first line treatment of metastatic
CRC [24-29]. Bevacizumab is a humanized monoclonal
antibody targeting the most important factor implicated
in tumor angiogenesis called vascular endothelial growth
factor (VEGF), and was the first molecule developed in
the treatment of metastatic CRC. In first line, it was
evaluated in randomized phase III trials in combination
with IFL (5FU/LV bolus and irinotecan), FOLFIRI, FOL-
FOX, and XELOX. These studies confirmed the benefit
of bavacizumab in ORR, PFS, and OS (table 1) [24-26].
Cetiximab is a chimeric monoclonal antibody targeting
the epidermal growth factor receptor (EGFR). Two ran-
domized trials in metastatic setting showed that adding
cetuximab to FOLFIRI or FOLFOX, improved outcomes
(ORR and PFS) in patients with K-RAS wild type tumors
(table 2) [28,29]. With the use of bevacizumab and
cetuximab in combination with CT, survival of patients
has improved to more than 24 months.
New staging system
A new staging system was proposed by the European
Colorectal Metastases Treatment Group (ECMTG) that
would subdivide the M from the TNM classification
into 4 groups [8]:
*M0: no metastases
*M1a: resectable liver metastases
*M1b: potentially resectable liver metastases
*M1c: liver metastases those are unlikely to ever
become resectable.
For both the M1a resectable patients and the M1b
patients who become resectable after systemic treat-
ment, resection offers the possibility of cure. For the
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not be excluded. Resection should be discussed in multi-
disciplinary team meetings.
Criteria of resectability
There are at least three categories of patients with
CRLM:
-First, the hepatic lesion(s) are clearly resectable at
the time of presentation.
-Second, the hepatic lesion(s) are unresectable at
presentation but potentially convertible to resection
after primary CT called conversion CT.
-Third, the hepatic lesion(s) are unresectable and are
unlikely to become resectable even with effective CT.
Relative contraindications of liver resection are syn-
chronous rectal cancer; multiple, diffuse or large liver
metastases; extrahepatic metastases; high level of ACE(>
200 ng/ml). In patients with no evidence of extrahepatic
disease, the main contraindications to liver resection are
tumors located close to the hepatic veins and inferior
vena cava or to the liver hilum, larges, or numerous
liver metastases. Contraindication usually results from a
combination of these main causes that precludes liver
resection with a sufficient margin of ≥ 1 cm. Curative
resection is exceptional for patients with more than 4
metastases. These systems were established before the
air of modern CT [6,30,31]
(A) French recommendations (FFCD)
The French recommendations divided the resectabil-
ity on different classes [32,33]:
*Resectability of class I; easily resectable by experi-
enced surgeons in liver surgery:
-Four or less than 4 segments involved and residual
healthy liver volume > 40%:
-Vena cava free from tumor;
-≤1 hepatic vein,
-Contra-lateral portal pedicule.
*Resectability of class II; potentially resectable metas-
tases by experienced surgeons in liver surgery: 5 to 6
segments involved ± contra-lateral major named vascu-
lar structures within liver. The hepatectomy is possible
by a complex or large resection (more than 4 segments)
that requires difficult and/or risky procedure (central
hepatectomy, extended right hepatectomy, vascular
reconstruction).
*Resection is not possible in the case of: (1) invol-
vement of two portals branches; (2) involvement of
one portal branch and a contra-lateral hepatic vein:
or (3) involvement of three hepatic veins.
Prognostic factors are: Size > 5 cm, number > 4, bilo-
bar character, invasion of pedicle lymph node, and/or
high level of ACE.
(B) Oncosurge system
The oncosurge system define the respectability as the
possibility of resection of all liver metastases with nega-
tive margins > 1 cm and a residual healthy liver volume
> 20%. In this system, the prognostic factors are the per-
formance status and the percentage of the underlying
healthy liver. The extrahepatic metastases (hilar lymph
Table 1 Randomized phase III trials evaluating Bevacizumab in combination with chemotherapy in first line treatment
of metastatic CRC
Trials in first line treatment Results
Trial name/Author No Treatments ORR (%) PFS (months)
(first end point)
OS (months)
Hurwitz (2004) [24] 813 IFL ± Bevacizumab 45 vs. 35 (p = 0.004) 10.6 vs. 6.2 (p < 0.001) 20.3 vs. 15.6 (p < 0.001)
BICC-C (2007) [25] 430 IFL/FOLFIRI ± Bevacizumab 57.9 vs. 53.3 (NS) 11.2 vs. 8.3 (p = 0.007) NR vs. 19.2 (p = 0.007)
NO 16966 (2008) [26] 1401 XELOX/FOLFOX ± Bevacizumab 47 vs. 49 (NS) 9.4 vs. 8 (p = 0.0023) 21.3 vs. 19.9 (p = 0.077)
Abbreviations. ORR: overall response rate; DFS: disease free survival; OS: overall survival
Table 2 Randomized phase III trials evaluating Cetuximab in combination with chemotherapy in first line treatment of
metastatic CRC
Trials in first line treatment
(K-RAS wild type)
Results
Trial name/Author No Treatments ORR (%) PFS (months)
(first end point)
OS (months)
CRYSTAL (2009) [28]
(phase 3)
599 FOLFIRI ± Cetiximab 59 vs. 43 (p = 0.03) 9.9 vs. 8.7
(HR = 0.68; 95% CI, 0.50 to 0.94)
23.5 vs. 20 (HR = 0.80)
OPUS (2009) [29]
(phase 2)
338 FOLFOX ± Cetuximab 61 vs. 37 (p = 0.01) 8.3 vs. 7.2 (HR = 0.57; p = 0.016) 22.8 vs. 18.5 (HR = 0.86)
Abbreviations. ORR: overall response rate; PFS: progression free survival; OS: overall survival
Ismaili World Journal of Surgical Oncology 2011, 9:154
http://www.wjso.com/content/9/1/154
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formal contraindication against surgery. Currentely
approximately 20% of the patients with liver metastases
can be resected, and have an estimated 5 years survival
of 50% [34].
Neoadjuvant chemotherapy
Neoadjuvant CT should be distinguished from conver-
sion CT, which is also administered in the pre-opera-
tive setting but is administered to patients with
initially unresectable disease, with the intention of
downsizing the tumor burden, and, ultimately, consid-
ering resection.
(A) Conversion chemotherapy in initially unresectable
colorectal liver metastases
Only a minority of patients with liver metastases is
amenable directly to surgery (15%). Therefore, efforts
have been made to increase the resectability of patients
with initially unresectable colorectal liver metastases.
T h ed o w n s i z i n go fC R L Mc a nh a v ean u m b e ro f
advantages:
(1) small metastases can disappear in one lobe allow-
ing resection of metastases in the opposite lobe;
(2) major vascular pedicles of the liver may become
free from tumor;
(3) large lesions may become accessible to ablative
techniques, when they shrink to less than 3 cm in
diameter.
The role of conversion CT was evaluated in numer-
ous retrospective and phase II studies [10,19,35-47]. In
a large surgical series of 1104 patients with initially
unresectable liver metastases, the 5 years survival of
the resected patient (12%) following primary CT was
33%, that approached the 5 years survival rate of the
resectable patients in the same period (equal to 48%)
[10]. In a retrospective French study, 131 patients with
unresectable liver metastases were included and
received 3- 6 months of CT. In 57 patients (44%),
curative surgery of liver metastases was considered
possible. After 39 months median follow-up, the 4
years survival in resected patients was 37%. The rate of
postoperative complication was 14% [35]. In addition,
prospective studies confirmed the ability of neoadju-
vant CT to render some metastases resectable. How-
ever, there is a wide differences in the liver resection
rates reported for theses different trials reflecting in
one part the differences in criteria for respectability/
unresectability that exist between the different centers,
in the absence of a clear definition. In another part,
theses differences can be explained by the CT regi-
mens used; in fact, FOLFOX, and FOLFIRINOX
showed to be the most effective protocols (table 3)
[19,36-47].
(B) Neoadjuvant chemotherapy in resectable colorectal liver
metastases
Neoadjuvant CT is the administration of chemotherapy
in the pre-operative setting in patients with resectable
Table 3 Published prospective trials evaluating the resectability rate after first line-chemotherapy in patients with
initially unresectable colorectal liver metastases
Auto (year) No Treatments ORR Resectability rate Perioperative complications
Wein (2001) [36] 53 5FU/LV 41% 11% Acceptable
Pozzo (2002) [37] 40 5FU/LV + irinotecan 47.5% 32.5% Acceptable
Cals (2004) [38] 34 5FU/LV + irinotecan + oxaliplatin 50% 15% Acceptable
Tourniguand (2004) [19] 109 FOLFOX 54% 22% Acceptable
111 FOLFIRI 56% 9% Acceptable
Kohne (2005) [39] 216 5FU/LV + irinitecan 62.2% 7% Acceptable
214 5FU/LV 34.4% 3% Acceptable
Ho (2005) [40] 40 5FU/LV/IRI 55% 10% Acceptable
Seium (2005) [41] 30 5FU/LV + irinotecan + oxaliplatin 78% 23% Hematological+++
Alberts (2005) [42] 42 FOLFOX 60% 40% Acceptable
Masi (2006) [43] 74 FOLFIRINOX 72% 26%
Ychou (2007) [44] 34 FOLFIRINOX 70.6% 26.5% Acceptable
Hematological+++
Falcone (2007) [21] 122 FOLFIRINOX 60% 15% Hematological+++
122 FOLFIRI 34% 6%
Skof E (2009) [46] 41 XELIRI 49% 24% Equivalent
46 FOLFIRI 48% 24%
Zhao R (2010) [47] 48 XELIRI 56.3% 42% Diarrhea+++
Abbreviations. ORR: overall response rate
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Page 4 of 12disease. It has a number of potential benefits:
(1) Increasing the percentage of resectability
(2) Achieving a limited hepatectomy
(3) Treatment of micro-metastases
(4) Evaluation of chemosensitivity of the disease and
thus provides guidance about whether CT should be
given after the resection of metastases.
T h em o s ti m p o r t a n ti n c o n v e n i e n to fn e o a d j u v a n tC T
is the progression of metastases during neoadjuvant CT.
The feasibility and the benefit of neoadjuvant CT have
been evaluated in phase 2 studies and in one phase III
randomized trial. In a phase 2 study (MIROX trial), the
liver resection was performed after six cycles of FOL-
FOX CT. The ORR was 77% and the curative resection
rate was 91%. The 2 year overall survival rate was 89%.
The treatment was generally well tolerated; the main
toxicities were grade 3 to 4 neutropenia and thrombocy-
topenia [48]. At present, only one randomized phase III
trial investigating the role of perioperative CT in
patients with resectable liver metastases has been pub-
lished in the English literature. This parallel-group study
conducted by the EORTC intergroup (EORTC Inter-
group trial 40983) reports the final data for PFS. Three
hundred 64 patients with colorectal cancer and up to 4
liver metastases were randomly assigned to either six
cycles (3 months) of FOLFOX4 before and six cycles (3
months) after surgery or to surgery alone (182 in perio-
perative CT group vs. 182 in surgery group) (Figure 1).
The primary objective was PFS. In the perioperative CT
group, 151 (83%) patients were resected vs. 152 (84%) in
t h es u r g e r yg r o u p .T h ea b s o l u t ei n c r e a s ei nr a t eo fP F S
at 3 years was 7.3% (p = 0.058) in randomised patients;
8 . 1 %( p=0 . 0 4 1 )i ne l i g i b l ep a t i e n t s ;a n d9 · 2 %( p=
0.025) in patients undergoing resection. Reversible post-
operative complications occurred more often in perio-
perative CT than group than in surgery alone group
(25% vs.1 6 % ;p=0 · 0 4 ) .O p e r a t i v em o r t a l i t yw a sl e s s
than 1% in both treatment groups [9].
The combination of targeted agents with cytotoxic
therapy showed high ORR and thus warrants assessment
in the perioperative setting [24-29]. At least 4 phases II
trials assessing the role of targeted therapies in preo-
perative setting were published (table 4) [49-52]. These
studies showed that bevacizumab and cetuximab in
combination with the standard CT improve ORR (70-
78%) and resectability rates (60-93%) in patient with
initially unresectable or potentially resectable CRLM,
without inacceptable perioperative complications. Sev-
eral randomized trials are ongoing to confirm theses
preliminaries results. In a p h a s eI I Is t u d yc o n d u c t e db y
the EORTC group [EORTC 40051 BOS (Biologics, Oxa-
liplatin and Surgery) trial] the investigators assess the
perioperative CT based on cetuximab plus FOLOFOX
with or without bevacizumab in patients with resectable
hepatic metastases from colorectal cancer [53]. In
another phase III study, the NCI group investigates the
benefit of adding cetuximab to FOLFOX in periopera-
tive setting [54].
Adjuvant chemotherapy
In the past, the standard treatment of patients with
resectable liver metastasis was surgical resection alone.
Thereafter, CT (neoadjuvant or adjuvant) was intro-
duced in the multidisciplinary management in light of
several investigations.
Adjuvant systemic CT is defined by the administration
of CT after complete resection of CRLM. It has the aim
to reduce the risk of recurrence and to improve patient
survival.
There are 2 theoretical rational for adjuvant CT after
liver resection: (1) the presence of cancer cells “dor-
mant” in the remaining liver; and (2) the benefit of adju-
vant CT after surgery for stage III colorectal cancers
[55].
In analogy to stage III disease, adjuvant CT or pseudo-
adjuvant CT was assessed after the complete resection
of all liver disease in two phase III trials using a similar
design, but closed prematurely because of slow accrual;
The pooled analysis based on individual data from these
two trials was also published. A third and fourth phase
III studies were conducted to compares two different
adjuvant CT regimens (table 5) [56-60].
In the first 2 phase III studies, the patients were ran-
domized between two arms, one experimental arm test-
ing adjuvant CT containing 5FU/LV bolus regimen for 6
months, and a control arm treated by surgery alone. In
the first study (Fédération Francophone de Cancérologie
Digestive [FFCD] Trial 9002)including 173 patients, the
differences in 5-year PFS and 5-year OS between the
two arms were not significant, 33.5% vs. 26.7% and 51%
Figure 1 The following figure shows the design of the EORTC
Intergroup randomized trial 40983.
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fit for CT in multivariate analysis (Cox model for PFS:
odds ratio = 0.66, P = 0.028) [57]. The second rando-
mized study is a multicenter study conducted by the
EORTC/NCIC/GIVIO group, (European Organization
for Research and Treatment of Cancer/National Cancer
Institute of Canada Clinical Trials Group/Gruppo Ita-
liano di Valutazione Interventi in Oncologia [ENG]
trial), including 129 patients. The results at 4 years did
not show any difference between the 2 groups either in
PFS (45% vs. 35%) and OS (57% vs. 47%) [56]. The
pooled analysis using the individual data from these two
studies was presented at the ASCO 2006 annual meeting
and was recently published. This meta-analysis showed a
marginal statistical significance in PFS (p = 0.095) and
OS (p = 0.058) in favor of adjuvant chemotherapy. In
addition, a multivariate analysis of three factors (treat-
ment groups, the number of metastases, and relapse-free
interval before metastasis), suggested the benefit for CT
[58].
A third randomized study comparing two adjuvant CT
treatments, FOLFIRI and 5FU/LV, was conducted and
recently published by a French team. Three hundred 22
completely resected (R0) patients were included in this
study. In the published article, the authors concluded
that there were no differences in PFS (first end point)
and in OS between the 2 CT arms. However, in the
patients treated early within 42 days of surgery, the
F O L F I R IC Ts a m et od ob e t t e rt h a n5 F U / L VC T( P F S :
p = 0.17) [59].
Finally, a fourth trial has compared adjuvant treatment
associating bevacizumab to XELOX vs. XELOX alone
after radical resection of CRLM. Due to slow accrual,
the study was closed early, after inclusion of 79 patients.
At last follow-up, the 2 year PFS survival rate (first end
point) was 70% vs. 52% in favor of Bevacizumab arm,
however, the difference was not significant (p = 0.074).
No significant differences in toxicity between the 2 arms
were found [60].
Liver injuries related to neoadjuvant chemotherapy
Although preoperative CT has many advantages, there
has been growing concern about the potential for hepa-
totoxicity. The types of injuries observed in the liver
specimens from patients treated with preoperative CT
include steatosis, steatohepatitis, and sinusoidal injuries.
These pathologies have showed to be drug specific as
well as related to the duration of CT.
(A) Steatosis and steatohepatitis
Steatosis is defined by the accumulation of lipids in the
hepatocyte. Its prevalence rages between 16 to 31%
increasing to 46-75% in heavily consumed alcohol and
obese patients. In the later stages, steatosis is accompa-
nied by inflammation and balloonisation which lead to
Table 4 Selected phase II trials investigating targeted therapies in preoperative setting
Auto (year) Type of
metastases
No Treatments Resectability
rate
ORR Perioperative
complications
Gruenberger
(2008) [49]
Potentially
resectable
56 Bevacizumab +
XELOX
93% 73% (CR = 8.9%; PR = 64.3%) Acceptable
Wong (2011)
[50]
Not suitable for
upfront resection
46 Bevacizumab +
XELOX
40% 78% No grade 3-4
complications
Shimada
(2011) [51]
Unresectable 7 Bevacizumab +
FOLFIRINOX
71% 100% No grade 3-4
complications
Folprecht
(2010) [52]
Unresectable 114 Cetuximab +
FOLFOX or FOLFIRI
60% 70% in K-RAS wild type tumors (R0 = 34%: 38%
with FOLFOX vs 30% with FOLFIRI)
Acceptable
Abbreviations. ORR: overall response rate; CR: complete response; PR: partial response; R0: complete resection with free margins
Table 5 Randomized trials and metaanalyses evaluating the role systemic adjuvant chemotherapy in patients with
completely resected colorectal liver metastases
Authors (year) Type of
study
No Randomized postoperative
chemotherapy
Median PFS (months) Median OS (months)
Langer B (2002)
[56]
Phase III 129 5FU/LV No difference No difference
Portier (2006) [57] Phase III 173 5FU/LV 24.4 vs. 16.6 (p = 0.028) 62.1 vs. 46.4 (p = 0.13)
Mirty (2006) [58] Pooled
analysis
278 5FU/LV 27.9 vs. 18..8 (p = 0.059) 61.1 vs. 46.9 (p =
0.125)
Ychou (2009) [59] Phase III 306 FOLFIRI vs. 5FU/LV 24.7 vs. 21.6 (p = 0.44) No difference
Voest (2011) [60] Phase III 79 Bevacizumab + XELOX vs. XELOX 2 years PFS = 70% vs. 52% (p =
0.074)
-
Abbreviations. PFS: progression free survival; OS: overall survival
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can lead to significant decrease in liver function. Over a
10-year period, approximately 9%-20% of patients with
steatohepatitis develop cirrhosis. Of the patients who
develop cirrhosis, 22%-33% of them develop end-stage
liver disease [61-66]. Analysis of the impact of steatosis
on outcome after liver resection suggests that morbidity
is increased but not mortality [67,68]. While steatohepa-
titis may be associated with increased 90-day mortality
due to liver failure after surgery [69].
(B) Vascular damage or sinusoidal obstruction syndrome
Sinusoidal obstruction syndrome results from damage to
endothelial cells lining the sinusoids of the liver [70,71].
It can lead to portal hypertension, ascites, hyperbilirubi-
nemia, and in severe cases, liver failure. One of the sign
of sinusoidal obstruction syndrome is sinusoidal dilation.
Analysis of the impact of vascular lesions on outcome
following liver resection suggests that sinusoidal injury
increases the risk of operative bleeding but does not
increase perioperative morbidity and mortality [69,72].
(C) Drug specific toxicity
Liver damage following CT has showed to be drug spe-
cific as well as related to the duration of CT. It was
reported that 5FU can be associated with an increased
risks of severe steatosis [73]. Oxaliplatin based combina-
tion regimen is associated with an increased risk of vas-
cular lesions of the liver [69,72,74]. In other reports,
irinotecan-containing regimens was associated with
increased risks of steatosis and steatohepatitis [67,69,75]
VEGF plays a critical role in liver regeneration. Con-
sequently, it is possible that hepatic regeneration could
be reduced in patients undergoing liver resection fol-
lowing VEGF blockage [76]. The results of 2 preclinical
investigations are inconsistent regarding the effect of
EGFR inhibition on hepatic regeneration; the first
study showed strong evidence that EGFR is essential in
hepatic regeneration, however, the second study
showed that cetuximab does not adversely affect liver
resection in mice [77,78]. Until further evidence is
obtained, it is reasonable to allow a 6/8 week interval
between the last administration of bevacizumab/cetuxi-
mab and surgery.
(D) The impact of chemotherapy duration
Two studies clearly showed that the morbidity rate is
related to the duration of CT administered. In the first
study with more than 12 courses of CT, was associated
with higher risk of post operative complications com-
pared with < or 12 courses. In the second study, the
authors showed that postoperative morbidity was higher
in patients receiving more than 6 cycles of CT before
surgery [72,79]. More recently, safety data of the
EORTC 40983/EPOC phase III study showed that the
administration of 6 cycles of FOLFOX before surgery
appears feasible; the mortality rate was very low (close
to 1%) and the rate of reversible complications was
acceptable [9].
Treatment recommendations (figure 2) [32,33,80]
Treatment choices for patients with CRLM should be
discussed in multidisciplinary team meetings (surgeon,
medical oncologist, radiation oncologist, radiologist,
pathologist...)
(A) Resectable colorectal liver metastases
Perioperative treatment with 3 months (6 cycles) of
FOLFOX4 CT was compatible with major liver surgery,
improved PFS in resectable patients, and should be con-
sidered as a standard of care in patients with resectable
CRLM.
Figure 2 The following figure summarizes the treatment recommendations.
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Page 7 of 12In the case of primary surgery, adjuvant CT based on
5FU/LV, FOLFOX4/XELOX or FOLFIRI regimens for 6
months should be considered as an option in patient
with completely resected liver metastases.
(B)Potentially resectable colorectal liver metastases
Neoadjuvant CT called conversion CT based on 3 months
(6 cycles) of FOLFOX4 or FOLFIRINOX regimens should
be considered to enhance the chance of cure of patient
with initially unresectable liver metastases. Resection
should be discussed in multidisciplinary team meetings.
(C)Liver metastases those are unlikely to ever become
resectable
Palliative CT based on FOLFOX4/XELOX, FOLFIRI,
with or without biological therapies should be
considered.
In this setting, the possibility of doing a resection
should not be excluded. Resection should be discussed
in multidisciplinary team meetings.
Table 6 summarizes the most used CT regimens in
metastatic CRC.
Table 6 The most used chemotherapy regimens in the treatment of metastatic colorectal cancer
Regimen Cycle
length
Drogues and doses
1 2 345
5FU Mayo
clinic
4 weeks LV 20 mg/m²/D on D 1-5 5FU 425 mg/m²/D
bolus on D 1-5
---
5FU/LV (de
Gramont) [17]
2 weeks LV 200 mg/m² over 2 h on D1
and D2
5FU 400 mg/m²
bolus on D1 and
D2
5FU 600 mg/m² CIVI
over 22 h on D1 and
D2
--
FOLFOX4 [17] 2 weeks Oxaliplatin 85 mg/m² over 2 h
on D1
LV 200 mg/m²
over 2 h on D1
and D2
5FU 400 mg/m²
bolus on D1 and D2
5FU 600 mg/m² CIVI
over 22 h on D1 and
D2
-
Modified
FOLFOX6
2 weeks Oxaliplatin 85 mg/m² over 2 h
on D1
LV 200 mg/m²
over 2 h on D1
and D2
5FU 400 mg/m²
bolus on D1
5FU 2400 mg/m² CIVI
over 46 h on D1
XELOX 3 weeks Oxaliplatin 130 mg/m² over 2
ho nD 1
Capecitabine 1 g/
m² BD on D1-14
---
FOLFIRI [19] 2 weeks Irinotecan 180 mg/m² over 1 h
on D1
LV 200 mg/m²
over 2 h on D1
and D2
5FU 400 mg/m²
bolus on D1 and D2
5FU 600 mg/m2 CIVI
over 22 h on D1 and
D2
-
XELIRI 3 weeks Oxaliplatin 130 mg/m² over 2
ho nD 1
Capecitabine 1 g/
m² BD on D1-14
---
FOLFIRINOX
(Italy) [21]
2 weeks Irinotecan 165 mg/m² over 1 h
on D1
Oxaliplatin 85 mg/
m² over 2 h on
D1
LV 200 mg/m² on D1 5FU 400 mg/m² bolus
on D1
5FU 3200 mg/m2
CIVI 48 h on D1
FOLFIRINOX
(France) [45]
2 weeks Irinotecan 180 mg/m² over 1 h
on D1
Oxaliplatin 85 mg/
m² over 2 h on
D1
LV 400 mg/m² on D1 5FU 400 mg/m² bolus
on D1
5FU 2400 mg/m2
CIVI 48 h on D1
Bevacizumab
+ FOLFOX4
[26]
2 weeks Bevacizumab 5 mg/kg over
30-90 min on D1
Oxaliplatin 85 mg/
m2 over 2 h D1
LV 200 mg/m² over
2h on D1 and D2
5FU 400 mg/m² bolus
on D1 and D2
5FU 600 mg/m² CIVI
over 22 h on D1 and
D2
Bevacizumab
+ XELOX [26]
3 weeks Bevacizumab 7.5 mg/kg over
30-90 min on D1
Oxaliplatin 130
mg/m² over 2 h
on D1
Capecitabine 1 g/m²
BD on D1-14
--
Bevacizumab
+ FOLFIRI [25]
2 weeks Bevacizumab 5 mg/kg over
30-90 min on D1
Irinotecan 180
mg/m² over 1 h
D1
LV 200 mg/m² over
2h on D1 and D2
5FU 400 mg/m² bolus
on D1 and D2
5FU 600 mg/m² CIVI
over 22 h on D1 and
D2
Cetuximab +
FOLFIRI
(K-RAS wild
type) [28]
2 weeks Cetuximab 400 mg/m² over 2
h on D1 then 250 mg/m²
weekly
Irinotecan 180
mg/m² over 1 h
on D1
LV 200 mg/m² over 2
h on D1 and D2
5FU 400 mg/m² bolus
on D1 and D2
5FU 600 mg/m² CIVI
over 22 h on D1 and
D2
Cetuximab +
FOLFOX
(K-RAS wild
type) [29]
2 weeks Cetuximab 400 mg/m² over 1
h on D1 then 250 mg/m²
weekly
Oxaliplatin 85 mg/
m² over 2 h on
D1
LV 200 mg/m² over
2h on D1 and D2
5FU 400 mg/m² bolus
on D1 and D2
5FU 600 mg/m2 CIVI
over 22 h D1 and D2
Abbreviations: D = day; CIVI = continuous intravenous infusion; BD = bid day
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Page 8 of 12Conclusion
The prognosis of patients with metastatic colorectal can-
cer of the liver has improved significantly over the last
few years (Figure 3). The management has become multi-
disciplinary using modern CT regimens and more devel-
oped surgical techniques. For patients with resectable
metastases, perioperative CT based on FOLFOX4 is the
treatment of choice before surgical resection according
to the results of the EORTC40983 randomized trial. For
patient with resectable metastases treated with primary
surgery, adjuvant CT is a reasonable option. In the case
of initially unresectable disease, conversion CT using
more active combination such as FOLFIRINOX should
be indicated to downsizing liver metastases and to opti-
mize the chance of cure. If metastases are unresectable
and unlikely to be resectable, palliative CT with or with-
out targeted agents is the mainstay treatment. The role of
targeted therapy in neoadjuvant setting will be defined in
the near future. Therapeutic investigations should be
continued with the development of more efficient regi-
mens, newer surgical and ablative techniques, to improve
treatment results of colorectal liver metastases.
Abbreviations
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